Q-omics provides the consensus-scored MIR181C profile across patient tissues and cancer cell-line models. MIR181C expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MIR181C is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MIR181C RNA expression shows 9,284 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, BRCA, and KIRP as cancer lineages where MIR181C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR181C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR181C survival associations across molecular data types. MIR181C RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR181C RNA expression–survival associations across cancer types. High MIR181C expression shows unfavorable associations in UVM, ACC, BRCA, KIRC and MESO, but favorable associations in ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MIR181C RNA expression.
This table summarizes MIR181C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR181C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR181C shows lower tumor expression in BRCA and higher tumor expression in THCA and KIRP. The BRCA box plot shows higher MIR181C RNA expression in normal versus tumor tissue (log2 FC = −0.134, t-test p = .003).
This table shows molecular features associated with MIR181C in patient tissues and cancer cell lines. In patient samples, MIR181C shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
